U.S. Markets close in 5 hrs 32 mins
  • S&P 500

    3,671.14
    +23.85 (+0.65%)
     
  • Dow 30

    29,316.26
    +181.27 (+0.62%)
     
  • Nasdaq

    10,863.59
    +34.08 (+0.31%)
     
  • Russell 2000

    1,679.34
    +16.83 (+1.01%)
     
  • Crude Oil

    80.12
    +1.62 (+2.06%)
     
  • Gold

    1,657.90
    +21.70 (+1.33%)
     
  • Silver

    18.62
    +0.29 (+1.57%)
     
  • EUR/USD

    0.9614
    +0.0017 (+0.1731%)
     
  • 10-Yr Bond

    3.8400
    -0.1240 (-3.13%)
     
  • Vix

    33.05
    +0.45 (+1.38%)
     
  • GBP/USD

    1.0714
    -0.0017 (-0.1596%)
     
  • USD/JPY

    144.3570
    -0.4340 (-0.2997%)
     
  • BTC-USD

    19,133.23
    -1,070.64 (-5.30%)
     
  • CMC Crypto 200

    436.73
    +7.95 (+1.85%)
     
  • FTSE 100

    6,982.92
    -1.67 (-0.02%)
     
  • Nikkei 225

    26,173.98
    -397.89 (-1.50%)
     

Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy

·1 min read
  • Mersana Therapeutics Inc (NASDAQ: MRSN) announced a global collaboration that provides GSK plc (NYSE: GSK) an exclusive option to co-develop and commercialize XMT-2056.

  • XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and tumor cells.

  • Mersana expects to initiate a Phase 1 trial of XMT-2056 to investigate its potential in a range of HER2-expressing tumors. The FDA recently granted an orphan drug designation to XMT-2056 for gastric cancer.

  • Mersana will receive an upfront option purchase fee of $100 million. Mersana also is eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option.

  • Mersana has retained options to profit-share and to co-promote in the U.S.

  • Mersana held cash, cash equivalents, and marketable securities of $225.1 million at the end of Q2. The company expects that its available funds, together with the $100 million option payment due from GSK, will be sufficient to support its operating plan commitments into 1H of 2024.

  • Price Action: MRSN shares closed 14.3% higher at $6.00 during after-hours trading on Monday. GSK stock is down 0.37% at $40.16 during the premarket session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.